| oseltamivir / Generic mfg. |
| Completed | 2b | 292 | US, Canada, Europe | VX-787 300 mg, JNJ-63623872, VX-787 600 mg, Oseltamivir 75 mg, Placebo | Janssen Research & Development, LLC, Janssen Pharmaceuticals | Influenza A | 05/16 | 05/16 | | |
| Completed | 2a | 101 | Europe | MHAA549A, Placebo, oseltamivir [Tamiflu] | Genentech, Inc. | Healthy Volunteer | 06/14 | 06/14 | | |
| Completed | 2 | 48 | US | Oseltamivir | National Institute of Allergy and Infectious Diseases (NIAID) | Influenza | 04/07 | 04/07 | | |
NCT00453999: Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza |
|
|
| Completed | 2 | 137 | US, Canada, RoW | Peramivir 200 mg, Peramivir 400 mg, Oseltamivir | BioCryst Pharmaceuticals | Influenza | 09/08 | 08/09 | | |
NCT00298233: High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza |
|
|
| Completed | 2 | 326 | RoW | Oseltamivir, Tamiflu | National Institute of Allergy and Infectious Diseases (NIAID), Wellcome Trust, World Health Organization, University of Oxford | Influenza, Avian Influenza, Severe Influenza | 01/10 | 01/10 | | |
ROSII, NCT01010087: Trial Comparing High Versus Standard Dose Oseltamivir in Severe Influenza Infection in ICU |
|
|
| Terminated | 2 | 59 | Canada | Oseltamivir, Tamiflu | University of Manitoba, Hoffmann-La Roche | Influenza A Virus | 05/11 | 05/11 | | |
NCT01037634: Safety and Efficacy of Oseltamivir in Children Younger Than One Year of Age |
|
|
| Withdrawn | 2 | 0 | US | Oseltamivir, Tamiflu | National Institute of Allergy and Infectious Diseases (NIAID) | Influenza | 03/12 | | | |
NCT01146535: Interferon Alpha Lozenges Plus Oseltamivir for Influenza Treatment |
|
|
| Completed | 2 | 40 | RoW | Interferon-alpha, IFN lozenge, Oseltamivir, Tamiflu, maltose, placebo | Ainos, Inc. (f/k/a Amarillo Biosciences Inc., CytoPharm, Inc. | Influenza A Virus Infection | 12/12 | 12/12 | | |
NCT02293863 / 2014-000461-43: A Study of MHAA4549A in Combination With Oseltamivir Versus Oseltamivir in Participants With Severe Influenza A Infection |
|
|
| Completed | 2 | 168 | Canada, Europe, RoW | MHAA4549A, Oseltamivir, Tamiflu, Placebo | Genentech, Inc. | Influenza | 05/17 | 05/17 | | |
NCT00867139: TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients |
|
|
| Completed | 1/2 | 7 | US | TCAD, Symmetrel, Rebetol, Tamiflu, Zanamivir or Oseltamivir, Relenza, Open label treatment with TCAD | Fred Hutchinson Cancer Center | Influenza | 08/09 | 01/10 | | |
NCT00391768: Oseltamivir Treatment for Children Less Than 24 Months of Age With Influenza |
|
|
| Completed | 1/2 | 87 | US, Canada | oseltamivir (Tamiflu®) | National Institute of Allergy and Infectious Diseases (NIAID) | Influenza | 03/10 | 04/10 | | |
NCT01179919: Pharmacokinetics of Oseltamivir Carboxylate In Morbidly Obese Subjects |
|
|
| Completed | 1/2 | 21 | US | Oseltamivir, Tamiflu | Manjunath Prakash Pai, Hoffmann-La Roche | Obesity | 09/10 | 12/10 | | |
